News

Categories

January 25, 2023

Zymeworks Announces Participation In Upcoming Investor Conferences

January 19, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

January 17, 2023

Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)

January 4, 2023

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

December 21, 2022

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

December 19, 2022

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

December 14, 2022

Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

December 9, 2022

New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

November 21, 2022

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

November 10, 2022

Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference

November 1, 2022

November is Stomach Cancer Awareness Month

October 20, 2022

Zymeworks Early R&D Day Highlights Progress In Development Of Novel Pipeline Assets And Applications Of Proprietary Next-Generation Technology Platforms